Indivior PLC (NASDAQ:INDV) Shares Acquired by Stonepine Capital Management LLC

Stonepine Capital Management LLC boosted its position in Indivior PLC (NASDAQ:INDV) by 13.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 305,000 shares of the company’s stock after acquiring an additional 35,000 shares during the quarter. Indivior accounts for 3.1% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 10th biggest position. Stonepine Capital Management LLC owned 0.22% of Indivior worth $3,791,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Indivior during the 4th quarter valued at approximately $56,000. Lazard Asset Management LLC acquired a new stake in Indivior in the fourth quarter valued at $57,000. Stifel Financial Corp boosted its stake in Indivior by 24.0% during the 4th quarter. Stifel Financial Corp now owns 12,675 shares of the company’s stock valued at $158,000 after acquiring an additional 2,450 shares during the last quarter. Rathbones Group PLC grew its holdings in Indivior by 11.6% during the 4th quarter. Rathbones Group PLC now owns 14,284 shares of the company’s stock worth $183,000 after acquiring an additional 1,483 shares in the last quarter. Finally, Gotham Asset Management LLC bought a new stake in shares of Indivior in the 4th quarter worth about $325,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Indivior Price Performance

Shares of INDV opened at $11.34 on Friday. The firm’s 50 day moving average is $10.11 and its 200-day moving average is $10.63. Indivior PLC has a 12-month low of $7.33 and a 12-month high of $18.59. The stock has a market capitalization of $1.56 billion, a P/E ratio of -32.40 and a beta of 0.98.

Indivior (NASDAQ:INDV) last announced its earnings results on Thursday, April 24th. The company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.22 by $0.19. The company had revenue of $266.00 million during the quarter, compared to analysts’ expectations of $240.13 million. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. As a group, equities research analysts forecast that Indivior PLC will post 1.22 EPS for the current fiscal year.

Analysts Set New Price Targets

INDV has been the subject of several research analyst reports. Piper Sandler lowered their price objective on Indivior from $16.00 to $13.00 and set an “overweight” rating for the company in a report on Thursday, March 6th. RODMAN&RENSHAW upgraded Indivior to a “strong-buy” rating in a research report on Tuesday, January 28th. Finally, Rodman & Renshaw initiated coverage on Indivior in a research report on Tuesday, January 28th. They set a “buy” rating and a $16.00 price target on the stock.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.